Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

He also serves as co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School.  

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:


    Silence Therapeutics
    Thomas Christély/Max Herrmann
    +49-30-9489-2800 / +44(0)20-7491-6520
    t.christely@silence-therapeutics.com
    m.herrmann@silence-therapeutics.com

 

    Singer Capital Markets
    Shaun Dobson/Claes Spång
    +44(0)20-32057500
    shaun.dobson@singercm.com
    claes.spang@singercm.com

 

    M:Communications (Europe)
    Peter Laing / Emma Thompson
    +44(0)20-7920-2345 / +44(0)20-7920-2342
    healthcare@mcomgroup.com


'/>"/>
SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company developing ... simulated embryonic conditions, today announced that they have entered ... for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell ... an amendment to the existing license between Histogen and ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... retains ownership of Pain Management business, NATICK, ... BSX ) today announced that it has completed ... business and drug pump,development program to former principals ... Bionics in 2004. The sale,coincides with the closing ...
... International,Associates, Inc., administrator for the HealthShares(TM) Indexes, a ... Funds,today announced that effective at the opening of ... MAXY ) will replace Aspreva Pharmaceutical,Inc. (Nasdaq: ... Inc. (NYSE: ALO ) will also replace ...
... with modest growth in the,traditional life science ... in agricultural, biodefense and molecular diagnostics. To,help ... and,advisory firm BioInformatics, LLC today released its ... of scientists working in,these dynamic markets. The ...
Cached Biology Technology:Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program 2Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program 3QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes 2Study Examines Media Preferences of Life Scientists in Applied Markets 2Study Examines Media Preferences of Life Scientists in Applied Markets 3
(Date:4/24/2014)... It,s broadly understood that the world,s oceans play ... exchange of carbon between Earth,s ecosystems and atmosphere. ... UC San Diego have taken a leap forward ... , When phytoplankton use carbon dioxide to make ... material is released into the sea as a ...
(Date:4/24/2014)... COLUMBIA, Mo. When bacteria attack plants, they ... cells to weaken and suppress natural defenses. However, ... the plant cells as a potential host. Now, ... and replicated the process that allows the bacteriaknown ... discovery could lead to natural anti-infective treatments that ...
(Date:4/24/2014)... April 24, 2014GEN Publishing recently introduced ... focusing on the application of OMICs technologies in ... sequencing, are beginning to transform medical care just ... the past decade-and-a-half. , "GEN,s editors and reporters ... genomics, metabolomics, transcriptomics, etc. etc. for years," said ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3Plants send out signals attracting harmful bacteria, MU study finds 2
... at Rice University bolster the case for costly and ... in small populations of endangered species. , Worldwide, zoos ... thousands of miles in order to breed them with ... need for such programs, which can stress rare animals, ...
... challenges , Chemists have discovered details about how the tadpole-shaped ... into the top-most surface of water, an insight expected ... environmental hazards. The findings of a team led by ... on the cover of the Sept. 8 issue of the ...
... at the University of Pennsylvania have demonstrated that morphine ... enhancing virus replication. The paper by Wang et al., ... appears in the November issue of The American Journal ... , Hepatitis C virus (HCV) is common among ...
Cached Biology News:Costly breeding programs for endangered species pay off 2Costly breeding programs for endangered species pay off 3Scientists discover new way to look at how molecules twist and turn on water 2Hepatitis C complicated by morphine withdrawal 2
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
With L-glutamine and potassium bicarbonate. Sterile, Insect cell culture tested...
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
Mol wt: average mol wt12,360.96 Da by calculation...
Biology Products: